Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

A prospective, multicentre, cohort study to assess the incidence of dengue illness in households from selected communities in Brazil (2014–2018)

2021; Elsevier BV; Volume: 108; Linguagem: Inglês

10.1016/j.ijid.2021.04.062

ISSN

1878-3511

Autores

Daniele Fernandes de Aguiar, Eliana Nogueira Castro de Barros, Guilherme S. Ribeiro, Patrícia Brasil, Maria Paula Gomes Mourão, Kléber Giovanni Luz, Francisco Hideo Aoki, André Ricardo Ribas Freitas, Guilherme Amaral Calvet, Eduardo A. Oliveira, Bianca F Branco, Ariane de Jesus Lopes de Abreu, Brigitte Cheuvart, Adrienne Guignard, Melanie de Boer, Ana Cláudia Duarte, Maria Beatriz Borges, Tatiana Guimarães de Noronha,

Tópico(s)

Viral Infections and Vectors

Resumo

To estimate the incidence of dengue infection across geographically distinct areas of Brazil.This prospective, household-based, cohort study enrolled participants in five areas and followed them up for up to 4 years (2014-2018). Dengue seroprevalence was assessed at each scheduled visit. Suspected dengue cases were identified through enhanced passive and active surveillance. Acute symptomatic dengue infection was confirmed through reverse-transcriptase quantitative polymerase chain reaction in combination with an antigenic assay (non-structural protein 1) and serology.Among 3300 participants enrolled, baseline seroprevalence was 76.2%, although only 23.3% of participants reported a history of dengue. Of 1284 suspected symptomatic dengue cases detected, 50 (3.9%) were laboratory-confirmed. Based on 8166.5 person-years (PY) of follow-up, the incidence of laboratory-confirmed symptomatic infection (primary endpoint) was 6.1 per 1000 PY (95% confidence interval [CI]: 4.5, 8.1). Incidence varied substantially in different years (1.8-7.4 per 1000 PY). The incidence of inapparent primary dengue infection was substantially higher: 41.7 per 1000 PY (95% CI: 31.1, 54.6).Our findings, highlighting that the incidence of dengue infection is underestimated in Brazil, will inform the design and implementation of future dengue vaccine trials.NCT01751139.

Referência(s)